November 2016

Rheonix to Present Data on User-Defined Tests and Next-Generation Sequencing Library Preparation with its Automated Molecular Testing Workstation

Company to showcase technology at AMP 2016 that streamlines assay workflows and improves efficiencies in research and clinical environments ITHACA, N.Y. — Rheonix Inc., a developer of fully automated molecular testing solutions, will highlight its Encompass Optimum™ workstation at the Association for Molecular Pathology (AMP) Annual Meeting Nov. 10-12 in Charlotte, North Carolina. The workstation simplifies many of the steps required to create customized user-defined assays by automating test performance and… Read More »
Rheonix COVID-19™ MDx Assay Receives Expanded FDA Emergency Use Authorization to Include Saliva as a Sample Type.
Learn More